Sign In
Buy PSX
$184.68
+2.12 (+1.16%)
At Close: Jun 03, 2026
Phillips 66's Q4 Earnings on Deck: Should You Stay Invested or Exit?
10:55am, Monday, 02'nd Feb 2026
PSX gears up for Q4 earnings with profit seen rebounding. However, falling revenues and a premium valuation raise questions for investors.
Stay Ahead of the Game With Phillips 66 (PSX) Q4 Earnings: Wall Street's Insights on Key Metrics
10:15am, Friday, 30'th Jan 2026
Beyond analysts' top-and-bottom-line estimates for Phillips 66 (PSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quart
How Phillips 66's Integrated Model Enhances Profitability & Resilience
10:55am, Thursday, 29'th Jan 2026
PSX gains from lower crude prices, boosting refining margins while its diversified business model supports steady cash flow and returns.
Phillips 66 (PSX) Advances While Market Declines: Some Information for Investors
07:16pm, Wednesday, 28'th Jan 2026
In the most recent trading session, Phillips 66 (PSX) closed at $142.08, indicating a +1.48% shift from the previous trading day.
Phillips 66 (PSX) Reports Next Week: Wall Street Expects Earnings Growth
11:00am, Wednesday, 28'th Jan 2026
Phillips 66 (PSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Oils and Energy Stocks Now
09:56am, Wednesday, 28'th Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Phillips 66 (PSX) Projected to Post Earnings on Wednesday
03:00am, Wednesday, 28'th Jan 2026
Phillips 66 (NYSE: PSX - Get Free Report) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Phillips 66 to post earnings of $2.24 per sh
Valero Energy vs. Phillips 66: Which Refining Stock Should You Bet On?
03:06pm, Tuesday, 27'th Jan 2026
VLO and PSX are set to gain as softer crude prices lift refining margins. However, PSX's diversified business model and exposure beyond refining stand out.
Phillips 66: Finally Positioned For A Refining Up-Cycle (With A Venezuela Kicker)
10:40am, Tuesday, 27'th Jan 2026
Phillips 66 is showing tangible improvement in its long-underperforming Refining Segment, driven by cost reductions, higher clean product yield, and record utilization rates. PSX benefits from discoun
Compass Wealth Management LLC Has $366,000 Stock Position in Phillips 66 $PSX
05:20am, Tuesday, 27'th Jan 2026
Compass Wealth Management LLC cut its stake in shares of Phillips 66 (NYSE: PSX) by 93.1% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investo
Chevron ramps up Venezuelan oil shipments as US tightens control
02:14pm, Monday, 26'th Jan 2026
Chevron (CVX) has expanded its Venezuelan crude shipments as US policy moves reshaped the country's oil flows following the capture of leader Nicolas Maduro. Th
Phillips 66 $PSX Shares Sold by Envestnet Portfolio Solutions Inc.
04:12am, Monday, 26'th Jan 2026
Envestnet Portfolio Solutions Inc. lowered its stake in shares of Phillips 66 (NYSE: PSX) by 31.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Co
Valero and Phillips 66 Buy Venezuelan Crude in Early U.S. Deal
01:46pm, Thursday, 22'nd Jan 2026
Valero (VLO) has emerged as one of the first U.S. Gulf Coast refiners to purchase Venezuelan crude under Washington's recent agreement with Caracas, a developme
Valero, Phillips 66 Jump on Cheap Venezuela Oil
01:37pm, Thursday, 22'nd Jan 2026
Valero Energy (VLO) and Phillips 66 (PSX) are wasting no time jumping back into Venezuelan crude, becoming some of the first U.S. refiners to lock in heavily di
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program
08:00am, Thursday, 22'nd Jan 2026
MELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, an
